Gibson is the co-founder and CEO of a nine-year-old company called Recursion Pharmaceuticals, which uses deep learning to hunt for novel therapeutic approaches to disease. Gibson is, in fact ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS.REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks ...

The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why. August 18, 2024 — 12:34 pm EDT Written by Alex Carchidi for The Motley Fool-> ...

Recursion completed a secondary offering this June that strengthened its cash reserves with an additional $200 million before fees. Unfortunately, the offering also inflated its share count.

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS.REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS.REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks ...